The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
ORGANIZATION
Shipments Restricted or Halted for 26.6% of Drugs in February: FPMAJ
As much as 26.6% of all ethical drugs in Japan saw their shipments either restricted or suspended in February, with the figure worsening from the prior month, according to the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ). The rate…
To read the full story
Related Article
- Shipments Curbed or Suspended for 25.9% of Drugs in January: FPMAJ
February 19, 2024
- Drug Supply Worsens for 3rd Month Running amid Flu Surge, Shipment Halts
February 13, 2024
- Shipments Curbed or Suspended for 22.9% of Products in September: FPMAJ
October 27, 2023
- Shipments Restricted or Halted for 22.9% of Products in August: FPMAJ
September 25, 2023
- Shipments Restricted or Suspended for 22.4% of Products in July, No Sign of Improvement: FPMAJ
August 31, 2023
- Shipments of 22.3% of Products Restricted or Suspended in June: FPMAJ
July 24, 2023
- Supplies of 15% of Drugs Restricted, Generics Account for 80%: FPMAJ
May 24, 2023
- Over 20% of All Generics under Restricted Shipments: FPMAJ
March 14, 2023
- FPMAJ Calls on Drug Makers to Lift Shipment Controls of 233 APIs/Specifications
December 28, 2022
- FPMAJ Poll Finds Worsening Supply Woes with 28% of Drugs Restricted or Suspended
December 7, 2022
- 20% of Listed Drugs in Japan, Mostly Generics, Hit by Supply Issues: FPMAJ Survey
November 22, 2021
ORGANIZATION
- EFPIA Japan, Patient Groups Call for Stronger Health Literacy, PPI
December 22, 2025
- JPMA Exec Renews Call for Simpler Drug Pricing System
December 19, 2025
- JGA to Create “Stable Supply Network” Membership to Expand Ramp-Up Scheme
December 18, 2025
- Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
- Japan Medical Societies Recommend RSV Vaccination for Older Adults
December 15, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…